GleamWall
中文EN

CLCS Cell Source, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1569340 · Fiscal year ends 12/31

Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.8%
TTM EPS YoY12.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,516.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6,985.4%
Debt / equity—
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-857.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue——
SG&A expense$1.94M$2.60M
Operating income-$3.84M-$4.33M
Pretax income-$4.51M-$5.32M
Net income-$4.51M-$5.32M
EPS (basic)-0.14-0.17
EPS (diluted)-0.14-0.17
Weighted avg. shares (diluted)41.87M37.79M
Balance sheet
Cash & equivalents$74,631$22,203
Total assets$286,500$195,171
Total liabilities$18.82M$15.81M
Shareholders' equity-$18.54M-$15.61M
Shares outstanding45.04M39.83M
Cash flow statement
Operating cash flow-$2.68M-$2.35M
Financing cash flow$2.74M$2.15M
Stock-based compensation$288,424$463,034

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.